Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남은미 | * |
dc.contributor.author | 조현지 | * |
dc.date.accessioned | 2022-10-27T16:31:03Z | - |
dc.date.available | 2022-10-27T16:31:03Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 2072-6694 | * |
dc.identifier.other | OAK-32401 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262619 | - |
dc.description.abstract | Simple Summary This study explored the characteristics, treatment, and survival outcomes of patients with pregnancy-associated breast cancer (PABC) in Korea. All patients of this study received standard treatments according to the National Comprehensive Cancer Network guideline. Compared to the non-PABC group, the PABC group had a lower percentage of hormone receptor positivity, increased HER2 overexpression, and higher Ki-67 levels. No maternal complications were observed in patients with PABC. In addition, the 5-year disease-free survival and overall survival rates were significantly poorer in the PABC group than in the non-PABC group. After adjusting for tumor characteristics, PABC was still associated with poor prognosis. This is the first report of the PABC population from a prospective cohort. Exploration to elucidate biologic relevance will follow. Background: Given that peak age of breast cancer (BC) is younger in Asians than in Western populations, relatively higher prevalence of pregnancy-associated breast cancer (PABC) has been reported. This study aimed to analyze the characteristics and clinical outcomes of PABC in Korea. Methods: We defined PABC as BC diagnosed during pregnancy or in the first postpartum year. We compared the clinicopathological characteristics and BC outcomes between patients with PABC and non-PABC patients in the prospective YBC cohort from Samsung Medical Center. Results: In total, 1492 patients were initially enrolled, and 1364 patients were included, of which 93 had PABC (6.8%). The median age of patients with PABC was 34 years. Hormone receptor expression was lower (64.6% vs 74.6%) and frequency of HER2 overexpression was higher (26.9% vs 17.6%) in patients with PABC than in non-PABC patients. The 5-year overall survival (OS) rates were 83.2% and 93.4% in patients with PABC and non-PABC patients, respectively (p < 0.001). The 5-year disease-free survival (DFS) rates were 72.2% and 83.8% in PABC and non-PABC patients. Conclusion: Compared to non-PABC patients, patients with PABC had poorer OS and DFS in this prospective cohort. Exploratory biomarker analysis for PABC is warranted. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | pregnancy | * |
dc.subject | breast cancer | * |
dc.subject | prospective cohort | * |
dc.title | Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort | * |
dc.type | Article | * |
dc.relation.issue | 19 | * |
dc.relation.volume | 14 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | CANCERS | * |
dc.identifier.doi | 10.3390/cancers14194839 | * |
dc.identifier.wosid | WOS:000866674600001 | * |
dc.identifier.scopusid | 2-s2.0-85139844608 | * |
dc.author.google | Jo, Hyunji | * |
dc.author.google | Park, Seri | * |
dc.author.google | Kim, Hye Ryeon | * |
dc.author.google | Kim, Hongsik | * |
dc.author.google | Hong, Joohyun | * |
dc.author.google | Lee, Jeong Eon | * |
dc.author.google | Yu, Jonghan | * |
dc.author.google | Chae, Byung Joo | * |
dc.author.google | Lee, Se Kyung | * |
dc.author.google | Ryu, Jai Min | * |
dc.author.google | Oh, Soo-young | * |
dc.author.google | Choi, Suk Joo | * |
dc.author.google | Kim, Ji-Yeon | * |
dc.author.google | Ahn, Jin Seok | * |
dc.author.google | Im, Young-Hyuck | * |
dc.author.google | Nam, Eun Mi | * |
dc.author.google | Nam, Seok Jin | * |
dc.author.google | Park, Yeon Hee | * |
dc.contributor.scopusid | 남은미(7005824288;57226666155) | * |
dc.contributor.scopusid | 조현지(57613468400) | * |
dc.date.modifydate | 20240301081003 | * |